What's Happening With VRTX Stock?
1. FDA approved Journavx, expected to achieve $4 billion in peak sales. 2. Vertex's revenue increased from $7.6 billion to $10.6 billion since 2021. 3. Operating margin declined from 51.4% in 2021 to 39.9% now. 4. Trikafta accounts for 93% of Vertex's total sales. 5. VRTX stock rose 106% from early 2022 to current levels.